Literature DB >> 28112337

[Potential neurocognitive consequences of infection by human respiratory syncytial virus].

Juan Carlos Flores1, Karen Bohmwald2, Janyra Espinoza2, Crlstlna Jara3, Marcela Peña3, Rodrigo Hoyos-Bachiloglu4, Carolina Iturriaga4, Alexis M Kalergis5, Arturo Borzutzky5.   

Abstract

Human respiratory syncytial virus (RSV) infection remains as a major cause of morbidity and mortality among pediatric population. Immune response is poor and unable to establish a long term effective protection against this virus. Of particular interest has been the description of extrapulmonary manifestations of RSV infection in liver, kidney, endocrine system, heart and brain, associated to infection of peripheral blood. In the central nervous system (CNS), recent studies in animals have suggested long term neurocognitive impairment due to a direct damage from the virus. This was prevented in rats by a recombinant BCG vaccine expressing a nucleoprotein N of RSV that produces an effective immune response against the virus, not allowing its dissemination to the CNS. These findings in animal models highlight the importance of conducting more specific studies in children affected with severe infection by RSV. Therefore, our group is currently conducting an assessment of the possible long-term cognitive impairment in children under 2 years. The results of this study could be a strong argument to continue looking for an effective method for protecting against RSV infection.

Entities:  

Mesh:

Year:  2016        PMID: 28112337     DOI: 10.4067/S0716-10182016000500008

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  1 in total

1.  Severe respiratory disease caused by human respiratory syncytial virus impairs language learning during early infancy.

Authors:  Marcela Peña; Cristina Jara; Juan C Flores; Rodrigo Hoyos-Bachiloglu; Carolina Iturriaga; Mariana Medina; Javier Carcey; Janyra Espinoza; Karen Bohmwald; Alexis M Kalergis; Arturo Borzutzky
Journal:  Sci Rep       Date:  2020-12-21       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.